Lobe Sciences Ltd. (LOBEF)
OTC PINK OTC PINK Primary 
Lobe Sciences eyes uplisting opportunities to enhance shareholder value
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF), a biopharmaceutical firm developing innovative medicines for rare diseases, told investors it is exploring strategic alternatives to improve shareholder value. The company said that among the alternatives it has been considering are uplisting opportunities, for example, listing on the Australian Securities Exchange or the New York Stock Exchange.
Lobe Sciences appoints management strategy expert to board
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced that Wesley Ramjeet will join its Board of Directors in the coming months. Ramjeet, who is the chief executive and Founder of PPMT Strategic Group, brings over two decades of strategic financial expertise to the biopharmaceutical company.
Lobe Sciences strengthens board with appointment of biopharma veteran
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced the appointment of Dr Frederick Sancilio to its board of directors. The company, which is focused on developing transformative medicines targeting rare diseases, highlighted that Dr Sancilio brings more than four decades of experience in pharmaceutical sciences and biopharmaceutical research to the position.
Lobe Sciences appoints Dr Harry Jacobson to its board
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF), a biopharmaceutical company developing transformative medicines for rare diseases, announced that Dr Harry Jacobson will join its board of directors. Dr.
Lobe Sciences announces change of control
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced a change in voting control of the company and enhancements to its growth strategy. The biopharmaceutical company said Clearway, a subsidiary of pharmaceutical services company Sancilio & Company which has been providing scientific support to Lobe for the past three years, has acquired voting control of the company following the completion of several transactions.
Lobe Sciences announces change of control
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced a change in voting control of the company and enhancements to its growth strategy. The biopharmaceutical company said Clearway, a subsidiary of pharmaceutical services company Sancilio & Company which has been providing scientific support to Lobe for the past three years, has acquired voting control of the company following the completion of several transactions.
